Health policy news

England & Wales health agency rejects two cancer drugs

Added: Thursday 29 September 2011

The National Institute for Health and Clinical Effectiveness (NICE), which makes recommendations to the NHS in England and Wales, has said that it will probably reject two cancer treatments. NICE has produced draft guidance stating that it could not recommend vinflunine, a treatment for the urothelial tract, or erlotinib, a lung cancer treatment. NICE cited both cost and evidence concerns as reasons for rejecting the drugs.